Generate Biomedicines, Inc.
NASDAQ:GENBAsset Management
+$0.13 today
- Market cap
- $1.34B
- Beta
- 0.19
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$4.06
Volume 1.05M
Average 0.55M
GENB Income Before Tax
Profit after all operating and non-operating items but before income tax.
Generate Biomedicines, Inc.NASDAQ: GENB
Income Before Tax · Q1 FY2026 · quarter ended Mar 2026
Income before tax of -$61.69M in Q1 FY2026
Q1 FY2026 income before tax was -$61.69M.
Context
- Income before tax amounted to 698.6% of revenue in FY2025, down 186.9 pp from a year earlier.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Before Tax history
USD · from the income statement
- Latest · FY2025
- (222.8M) USD
- Year-over-year change
- -23.0%
| Period | Period end | Income Before Tax | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (222.8M) | -23.0% |
| FY2024 | 2024-12-31 | (181.17M) | — |
Income Before Tax vs competitors
How GENB compares with its peers on the latest reported figures
- GENB's FY2025 income before tax of -$222.8M is the lowest of the 5 companies compared; the peer median is -$141.95M.
- Its year-over-year change of -23.0% is the 4th highest of 5, against a peer median of +3.2%.
- Income before tax amounts to 698.6% of revenue for GENB, versus a peer median of 3348.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$118.35M | -10.2% | — | 6445.8% | |
| LTM Mar 2026 | -$130.18M | -107.6% | — | 10014.1% | |
| LTM Mar 2026 | -$153.72M | +36.7% | — | 154.3% | |
| LTM Sep 2026 | -$170.81M | +16.6% | — | 251.7% | |
GENBGenerate Biomedicines, Inc. | FY2025 | -$222.8M | -23.0% | — | 698.6% |
| Peer median (excluding GENB) | -$141.95M | +3.2% | — | 3348.8% | |
Competitors are the stored peer set for GENB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Revenue | 20.46M | 31.89M |
| Cost of Revenue | 0 | 0 |
| Gross Profit | 20.46M | 31.89M |
| Gross Margin | 100.0% | 100.0% |
| Research & Development | 175.31M | 224.7M |
| Selling, General & Admin | 42.09M | 42.26M |
| Operating Expenses | 217.4M | 266.96M |
| Depreciation & Amortization | 15.35M | 13.18M |
| EBITDA | (163.71M) | (208.49M) |
| EBITDA Margin | -800.2% | -653.7% |
| Operating Income | (196.94M) | (235.07M) |
| Operating Margin | -962.6% | -737.0% |
| Interest Income | 18.12M | 13.66M |
| Interest Expense | 2.12M | 1.14M |
| Other Income / Expenses | 15.77M | 12.26M |
| Income Before Tax | (181.17M) | (222.8M) |
| Pre-Tax Margin | -885.5% | -698.6% |
| Income Tax Expense | 212K | 163K |
| Net Income | (173.77M) | (203.15M) |
| Net Margin | -849.4% | -637.0% |
| EPS (Basic) | (1.68) | (4.98) |
| EPS (Diluted) | (1.68) | (4.98) |
| Weighted Avg Shares | 127.45M | 50.09M |
| Weighted Avg Shares (Diluted) | 127.45M | 50.09M |
Generate Biomedicines, Inc.
NASDAQ:GENB
Intrinsic Alpha fair value
Locked
Current Price
$10.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.